الفهرس | Only 14 pages are availabe for public view |
Abstract Rosacea is a chronic relapsing inflammatory skin disease with a high prevalence among adults with fair skin, manifested by a variety of clinical presentations with various combinations of cutaneus symptoms including central flushing, erythema, telangiectasia, edema, papules, pustules, rhinophyma and ocular symptoms. There are many modalities for treatment that focused on symptom suppression to improve patient’s quality of life, prevent progression, and sustain remission but there is no ideal treatment without side effects. Platelet-rich plasma is an autologous concentration of human platelets in small volume of plasma. it contains effective concentration of multiple GFs, cytokines and plasma protein that assist in tissue remodling and wound healing. it contain bioactive factors that can modulate of inflammation giving the PRP antibacterial and anti-inflammatory effect. The aim of this study was to evaluate the efficacy and the safety of platelet rich plasma injection as a novella therapeutic intervention for treatment of patients with rosacea. The present study was carried on 20 patients with rosacea. they were collected from the Outpatient Clinics of Dermatology and Venereology Department in Tanta University Hospital. They received treatment in the form of PRP injection sessions in the right side of the face (group A) and PPP injection sessions in the left side (group B) one session every 2 weeks for 6 sessions. For all patients, the rosacea lesions were assessed before starting treatment, after the last session and after 3 months follow up according to RGS Skin punch biopsies were taken from the skin lesion before treatment and after completion of sessions. They were kept in formalin 10% and imbedded in paraffin for histopathological examination using hematoxylin and eosin stains and to demonstrate histopathological skin changes and effect of treatment. The results of the study showed the following Clinical results This study included 20 patients (18 females, 2 males) with different clinical severity of rosacea. their ages ranged from 32-65 with a mean 43.90 ± 11.04. there were 4 menopaused patients 20%. The family history was positive in 2 patients 10% The duration of the disease ranged from 1 year to 10 years with a mean 3.30 ± 2.79 years. The skin type of the patients was type III in 90% and type IV in 10%. Results of the evaluation of the efficacy of treatment: In group A: There was statistically significant difference in severity in rosacea lesions before and after treatment as the severity decreased There was significant improvement in the rosacea lesions after treatment with PRP when compared to the state of lesions before treatment as: 50% of patients showed good improvement and 50% of the patients showed excellent improvement. There was also statistically significant difference between group A and group B after treatment in which group A showed better improvement than group B. Regarding patient satisfaction: 60% were satisfied, 40% were very satisfied with no patients who were unsatisfied or slightly satisfied. There were statistically significant difference regarding patient satisfaction in group A and in group B with better patient satisfaction in group A than group B. group B: There was statistically significant difference in severity of rosacea lesions before and after treatment. There was significant improvement in rosacea lesions after treatment 10% of patients showed mild improvement,40% of patients showed moderate improvement, 50% showed good improvement, no patients showed excellent improvement. Regarding patient satisfaction: no patient were very satisfied,40% were unsatisfied, 45% were slightly satisfied 15% were satisfied. Regarding side effects after injection in both group: Pain during injection occurred in all patients 100% but it was mild to moderate. dryness occurred in 60% of the patients that persist for 3 days after injection. Erythema after injection immediately occur in all patients 100% but only 4 patients 20% complained of persistence of erythema for three days. Itching occurred in 30% of the patient. Edema at site of injection was found in 40%. |